AAN 2024: PrimeC found to lower nerve damage biomarker in trial
NeuroSense Therapeutics’ investigational therapy PrimeC tends to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve…
Articles by Lindsey Shapiro, PhD
AAN 2024: Trial investigator shares details from Relyvrio failure in ALS
While the now-discontinued amyotrophic lateral sclerosis (ALS) therapy Relyvrio (sodium phenylbutyrate and taurursodiol) failed to show a meaningful…
Environmental exposure to home chemicals tied to increased ALS risk
Storing chemicals such as gasoline, lawn care products, and paints in a garage attached to a home was associated with…
FDA OKs Phase 3b trial design for NurOwn in less advanced ALS
The U.S. Food and Drug Administration (FDA) has agreed on the design of a Phase 3b trial that will test…
Infusion therapy SLS-005 fails to slow ALS progression in trial
SLS-005 did not significantly slow amyotrophic lateral sclerosis (ALS) progression compared with a placebo in the HEALEY platform…
Efficacy of riluzole given by intrathecal delivery OK’d for study
Brain Trust Bio (BTB) has been cleared to launch Phase 1 clinical trials in Australia to test the efficacy…
Cryptic protein fragments may detect ALS in early stages: Study
A biomarker test that identifies abnormal protein fragments called cryptic peptides may help detect amyotrophic lateral sclerosis (ALS) and…
Research identifies ways CNM-Au8 can effectively reach the brain
When investigational amyotrophic lateral sclerosis (ALS) therapy CNM-Au8 reaches the bloodstream, it attracts a layer of proteins called a…
CNM-Au8 extends patient survival in 2 ALS compassionate use studies
Treatment with CNM-Au8 was shown to significantly prolong survival — relative to the natural history of the disease —…
Denali therapy candidate fails to slow ALS progression in trial
Denali Therapeutics’ SAR443820 (DNL788) treatment candidate — now in late-stage clinical testing for amyotrophic lateral sclerosis (ALS), per the…